Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial

The Lancet

Volumn 375, Issue 9710, 2010, Pages 201-209

  Kedhi, Elvin ^a   Joesoef, Kaiyum Sheik ^a   McFadden, Eugene ^a   Wassing, Jochem ^a   van Mieghem, Carlos ^a   Goedhart, Dick ^b   Smits, Pieter Cornelis ^a  

^a Maasstad Hospital Rotterdam   (Netherlands)

^b CARDIALYSIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PACLITAXEL;

ADULT; AGED; ARTICLE; BARE METAL STENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT THROMBOSIS;

EID: 73949122498     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)62127-9     Document Type: Article

References (19)

1. Morice M.C., Serruys P.W., Eduardo S.J., et al., the RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
2. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
3. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
4. Ong A.T., Serruys P.W., Aoki J., et al. The unrestricted use of paclitaxel-versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. JACC 45 (2005) 1135-1141
5. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomised clinical trial of drug eluting stents. N Engl J Med 356 (2008) 1020-1029
6. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
7. Serruys P.W., Morice M.C., Kappetein A.P., and SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360 (2009) 961-972
8. Stone G.W., Midei M., Newman W., et al., SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299 (2008) 1903-1913
9. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 21 (2000) 1502-1513
10. Cutlip D.E., Windecker S., Mehran R., et al. Clinical endpoints in coronary stent trials-a case for standardized definitions. Circulation 115 (2007) 2344-2351
11. Windecker S., Remondino A., Eberli F.R., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353 (2005) 653-662
12. Serruys P.W., Ruygrok P., Neuzner J., et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2 (2006) 286-294
13. Stokes M.E., Davis C.S., and Koch G.G. Categorical data analysis using the SAS System (1995), SAS Institute, Cary
14. Pocock S.J., Clayton T.C., and Altman D.G. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 359 (2002) 1686-1689
15. Joner M., Nakazawa G., Finn A.V., et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 52 (2008) 333-342
16. Onuma Y., Kukreja N., Piazza N., et al. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. J Am Coll Cardiol 54 (2009) 269-276
17. Dibra A., Kastrati A., Mehilli J., et al., ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 (2005) 663-670
18. Billinger M., Beutler J., Taghetchian K.R., et al. Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. Eur Heart J 29 (2008) 718-725
19. Turco M.A., Ormiston J.A., Popma J.J., et al. Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trial. J Am Coll Cardiol 49 (2007) 1676-1683